AxoGen (NASDAQ:AXGN) Price Target Raised to $22.00 at Canaccord Genuity Group

AxoGen (NASDAQ:AXGN) had its price objective lifted by Canaccord Genuity Group from $18.00 to $22.00 in a research report released on Monday morning,Benzinga reports. The firm currently has a buy rating on the medical equipment provider’s stock.

Separately, StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th.

AxoGen Trading Down 1.6 %

Shares of AxoGen stock opened at $17.92 on Monday. The firm has a 50-day simple moving average of $16.25 and a two-hundred day simple moving average of $13.88. The company has a market cap of $788.66 million, a P/E ratio of -56.00 and a beta of 1.00. AxoGen has a fifty-two week low of $5.55 and a fifty-two week high of $19.06. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

Institutional Trading of AxoGen

Institutional investors and hedge funds have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of AxoGen during the fourth quarter worth about $30,000. Quest Partners LLC increased its stake in shares of AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 2,076 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of AxoGen during the third quarter worth about $56,000. Oppenheimer & Co. Inc. purchased a new stake in shares of AxoGen during the third quarter worth about $156,000. Finally, Quantbot Technologies LP purchased a new stake in AxoGen during the 3rd quarter valued at about $165,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.